<p>UCB 宣布了来自第 3 期 BE BOLD 试验第 16 周的新结果，显示 bimekizumab 在活跃性银屑病关节炎成人患者中提供了优于 risankizumab 的关节结果。</p>
<p>在 2026 年伦敦 EULAR 年会上发布的数据标志着首个获批生物制剂在银屑病关节炎的头对头研究中显示出统计学上显著的关节结果优越性。</p>
<p>主要终点达成，接受 bimekizumab 治疗的患者中有 49.1% 在第 16 周达到了 ACR50，而接受 risankizumab 治疗的患者中为 38.4%。</p>
<p>在次要终点上也观察到了改善，尽管这些结果在预先指定的测试层级中未达到统计学显著性。bimekizumab 在所有次要指标上的反应均高于数值。</p>
<p>格拉斯哥大学的 Iain McInnes 教授表示：“提供高水平的临床反应对银屑病关节炎患者至关重要。在临床试验中达到 ACR50 水平的反应表明关节改善，与疾病活动性、炎症控制及随之而来的生活质量改善密切相关。</p>
<p>“新的 BE BOLD 数据显示，bimekizumab 在直接头对头试验设计中在第 16 周的 ACR50 上优于 risankizumab，可以支持临床医生在治疗这种慢性炎症性疾病时做出早期知情决策。”</p>
<p>UCB 的执行副总裁 Emmanuel Caeymaex 表示：“我们很自豪地宣布结果，证明 bimekizumab 在改善关节结果方面优于 risankizumab，提供了重要证据，可以为银屑病关节炎的治疗格局提供指导。</p>
<p>“头对头试验是比较临床研究中最严格的方法。BE BOLD 反映了 UCB 对科学卓越的承诺，通过生成高质量的证据，支持改善银屑病患者的护理。”</p>
<p>早期的关节改善在第 4 周就已显现，接受 bimekizumab 治疗的患者中有 19.9% 达到了 ACR50，而接受 risankizumab 治疗的患者中为 7.2%。在第 16 周，接受 bimekizumab 的患者中有 53.4% 实现了完全皮肤清除（PASI100），而接受 risankizumab 的患者中为 46.6%。</p>
<p>未发现新的安全信号。bimekizumab 的念珠菌感染发生率较高，但均为轻度或中度，且没有病例导致停药。治疗出现的不良事件发生率在治疗组之间相当，停药率低且相同。</p>

UCBJY

标普生物技术 3 倍做多 - Direxion

<p>UCB 宣布其 3 期 BE BOLD 试验的积极结果，显示 bimekizumab 在治疗活动性银屑病关节炎方面优于 risankizumab。在第 16 周，49.1% 的 bimekizumab 患者达到了 ACR50，而 risankizumab 的比例为 38.4%。早期改善在第 4 周就已显现。虽然没有报告新的安全隐患，但 bimekizumab 患者中轻度至中度的念珠菌感染更为常见</p>

<p>UCB has announced new week 16 results from the phase 3 BE BOLD trial showing that bimekizumab delivered superior joint outcomes to risankizumab in adults with active psoriatic arthritis.</p>
<div class="lb-trans"><p>UCB 宣布了来自第 3 期 BE BOLD 试验第 16 周的新结果，显示 bimekizumab 在活跃性银屑病关节炎成人患者中提供了优于 risankizumab 的关节结果。</p>
</div><p>The data, presented at the 2026 EULAR Annual Meeting in London, mark the first time an approved biologic has demonstrated statistically significant superiority in joint outcomes in a head‑to‑head psoriatic arthritis study.</p>
<div class="lb-trans"><p>在 2026 年伦敦 EULAR 年会上发布的数据标志着首个获批生物制剂在银屑病关节炎的头对头研究中显示出统计学上显著的关节结果优越性。</p>
</div><p>The primary endpoint was met, with 49.1% of patients receiving bimekizumab achieving ACR50 at week 16 compared with 38.4% receiving risankizumab.</p>
<div class="lb-trans"><p>主要终点达成，接受 bimekizumab 治疗的患者中有 49.1% 在第 16 周达到了 ACR50，而接受 risankizumab 治疗的患者中为 38.4%。</p>
</div><p>Improvements were also seen across secondary endpoints, although these did not reach statistical significance within the prespecified testing hierarchy. Numerically higher responses were observed for bimekizumab across all secondary measures.</p>
<div class="lb-trans"><p>在次要终点上也观察到了改善，尽管这些结果在预先指定的测试层级中未达到统计学显著性。bimekizumab 在所有次要指标上的反应均高于数值。</p>
</div><p>Professor Iain McInnes, University of Glasgow, said: “Delivering high-level clinical responses is crucial for people with psoriatic arthritis. Achieving ACR50 level responses in clinical trials indicates joint improvements that correlate closely with clinically meaningful reductions in disease activity, inflammation control and consequent improvements in quality of life.</p>
<div class="lb-trans"><p>格拉斯哥大学的 Iain McInnes 教授表示：“提供高水平的临床反应对银屑病关节炎患者至关重要。在临床试验中达到 ACR50 水平的反应表明关节改善，与疾病活动性、炎症控制及随之而来的生活质量改善密切相关。</p>
</div><p>“The new BE BOLD data, showing bimekizumab achieved superiority vs risankizumab in ACR50 at Week 16 in a direct head-to-head trial design, can support clinicians in making early informed decisions for treating this chronic inflammatory disease.”</p>
<div class="lb-trans"><p>“新的 BE BOLD 数据显示，bimekizumab 在直接头对头试验设计中在第 16 周的 ACR50 上优于 risankizumab，可以支持临床医生在治疗这种慢性炎症性疾病时做出早期知情决策。”</p>
</div><p>Emmanuel Caeymaex, Executive Vice President at UCB, said: “We are proud to announce results demonstrating the superiority of bimekizumab over risankizumab in improving joint outcomes, providing significant evidence that can inform the treatment landscape for psoriatic arthritis.</p>
<div class="lb-trans"><p>UCB 的执行副总裁 Emmanuel Caeymaex 表示：“我们很自豪地宣布结果，证明 bimekizumab 在改善关节结果方面优于 risankizumab，提供了重要证据，可以为银屑病关节炎的治疗格局提供指导。</p>
</div><p>“Head-to-head trials are the most rigorous approach to comparative clinical research. BE BOLD reflects UCB’s commitment to scientific excellence through generating high-quality evidence, that supports advancing care for people living with psoriatic disease.”</p>
<div class="lb-trans"><p>“头对头试验是比较临床研究中最严格的方法。BE BOLD 反映了 UCB 对科学卓越的承诺，通过生成高质量的证据，支持改善银屑病患者的护理。”</p>
</div><p>Early joint improvements were seen as soon as week 4, with 19.9% of patients on bimekizumab achieving ACR50 compared with 7.2% on risankizumab. Complete skin clearance (PASI100) at week 16 was achieved by 53.4% of those receiving bimekizumab and 46.6% receiving risankizumab.</p>
<div class="lb-trans"><p>早期的关节改善在第 4 周就已显现，接受 bimekizumab 治疗的患者中有 19.9% 达到了 ACR50，而接受 risankizumab 治疗的患者中为 7.2%。在第 16 周，接受 bimekizumab 的患者中有 53.4% 实现了完全皮肤清除（PASI100），而接受 risankizumab 的患者中为 46.6%。</p>
</div><p>No new safety signals were identified. Candida infections were more frequent with bimekizumab but were mild or moderate, and no cases led to discontinuation. Rates of treatment‑emergent adverse events were comparable between treatment arms, with low and identical discontinuation rates.</p>
<div class="lb-trans"><p>未发现新的安全信号。bimekizumab 的念珠菌感染发生率较高，但均为轻度或中度，且没有病例导致停药。治疗出现的不良事件发生率在治疗组之间相当，停药率低且相同。</p>
</div>

UCB 报告 bimekizumab 在银屑病关节炎治疗中取得了积极成果